`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`
`
`
`
`
`
`Civil Action No. 18-202-IMK
`
`
`
`
`
`)))))))))))
`
`
`
`
`ANACOR PHARMACEUTICALS, INC.,
`
`
`Plaintiff,
`
`
`
`v.
`
`
`MYLAN PHARMACEUTICALS INC., and
`MYLAN INC.,
`
`
`Defendants.
`
`
`
`ANACOR’S MOTION TO CONTINUE DEADLINES IN FIRST ORDER AND NOTICE
`REGARDING DISCOVERY AND SCHEDULING
`
`Plaintiff Anacor Pharmaceuticals, Inc. (“Anacor”) hereby moves to continue all deadlines
`
`set in this Court’s First Order and Notice Regarding Discovery and Scheduling, entered on
`
`December 14, 2018 (D.I. 20). Counsel for Mylan has represented that Mylan does not oppose
`
`the relief sought by this motion.
`
`As described in more detail in Anacor’s recently-filed Motion to Stay Case (D.I. 25), the
`
`Patent Trial and Appeal Board (“PTAB”) has instituted inter partes review proceedings (“IPRs”)
`
`that will address every patent claim at issue in this litigation. As Anacor also notes in its stay
`
`motion, Anacor also has filed a motion with the Judicial Panel on Multidistrict Litigation
`
`(“JPML”) seeking to transfer this case to the District of Delaware. See D.I. 25. Although the
`
`parties may not agree on the precise terms of Anacor’s stay proposal, Anacor understands that
`
`Mylan does not dispute the general proposition that a stay of this action is appropriate at least
`
`“until the [PTAB] issues final written decisions in the ongoing [IPRs] of the four patents-in-
`
`suit.” Anacor Pharma., Inc. v. Mylan Pharma., Inc., No. 18-1699-RGA (D. Del. Jan. 9, 2019),
`
`D.I. 21 (Brief in Support of Mylan’s Response to Anacor’s Cross-Motion to Stay).
`
`
`
`Case 1:18-cv-00202-IMK Document 37 Filed 01/17/19 Page 2 of 3 PageID #: 1312
`
`Accordingly, to avoid the unnecessary expenditure of resources by the Court and the
`
`parties on matters that may be mooted, Anacor respectfully requests that the Court continue the
`
`deadlines set in its December 14, 2018 order until this Court rules on Anacor’s Motion to Stay
`
`Case (D.I. 25).
`
`
`Dated: January 16, 2019
`
`
`
`OF COUNSEL:
`Aaron P. Maurer
`David I. Berl
`David M. Horniak
`Anthony Sheh
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`(202) 434-5000
`(202) 434-5029 (Facsimile)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
`
`SCHRADER COMPANION DUFF & LAW, PLLC
`
`
`/s/ James F. Companion
`James F. Companion
`401 Main Street
`Wheeling, WV 26003
`(304) 233-3390
`jfc@schraderlaw.com
`
`Attorneys for Plaintiff Anacor
`Pharmaceuticals, Inc.
`
`2
`
`
`
`Case 1:18-cv-00202-IMK Document 37 Filed 01/17/19 Page 3 of 3 PageID #: 1313
`
`CERTIFICATE OF SERVICE
`
` I
`
`
`
`
`
`
`
`
`
` hereby certify that on January 17, 2019, I caused a true and correct copy of the foregoing
`ANACOR’S MOTION TO CONTINUE DEADLINES IN FIRST ORDER AND NOTICE
`REGARDING DISCOVERY AND SCHEDULING to be electronically filed with the Clerk of
`the Court using the CM/ECF system, which will send notification of such filing to all counsel of
`record as follows:
`
`
`
`Gordon H. Copland, Esq.
`Gordon.Copland@steptoe-johnson.com
`William J. O’ Brien, Esq.
`William.Obrien@steptoe-johnson.com
`Steptoe & Johnson PLLC
`400 White Oaks Blvd.
`Bridgeport, WV 26330
`
`T.O. Kong
`tkong@wsgr.com
`Wendy L. Devine
`wdevine@wsgr.com
`Kristina M. Hanson
`thanson@wsgr.com
`Anjali Deskmukh
`adeshmukh@wsgr.com
`Wilson Sonsini Goodrich & Rosati
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, CA 94105
`
`Counsel for Defendants Mylan Pharmaceuticals Inc. and Mylan Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ James F. Companion
`
`Of Counsel
`
`
`
`3
`
`